Invesaro

Stocks Health care MRK

NYSE · Health care

Merck & Co., Inc. (MRK)

Merck & Co., Inc. brought in $66.6B of revenue over the twelve months to June 30, 2026, up 4.6% from a year earlier. Net income was $3.2B, a net margin of 4.8%. Operating cash flow minus capital spending left $12.4B of free cash flow in fiscal 2025. At June 30, 2026 it held $6.8B in cash against $51.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Price
$148.78
+0.54% on the day · September 25, 2026
52-week range $78.03 to $156.92
Market cap
$367.1B
Revenue (last 12 months)
$66.6B
+4.6% year on year
Net margin
4.8%
P/E
20.4
on FY2025 diluted EPS

What Merck & Co., Inc. does

Merck & Co. develops and manufactures prescription medicines, vaccines, and animal health products. The company sells its drugs to hospitals, pharmacies, and healthcare providers worldwide. It is known for producing cancer therapies, diabetes treatments, and vaccines for human and animal use. Its shares trade on NYSE under the ticker MRK.

Revenue and profit by year

Revenue
FY18: $42.3B $42.3B FY18FY19: $39.1B $39.1B FY19FY20: $41.5B $41.5B FY20FY21: $48.7B $48.7B FY21FY22: $59.3B $59.3B FY22FY23: $60.1B $60.1B FY23FY24: $64.2B $64.2B FY24FY25: $65B $65B FY25
Net income
FY18: $6.2B $6.2B FY18FY19: $9.8B $9.8B FY19FY20: $7.1B $7.1B FY20FY21: $13B $13B FY21FY22: $14.5B $14.5B FY22FY23: $365M $365M FY23FY24: $17.1B $17.1B FY24FY25: $18.3B $18.3B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$65Bn/a$18.3B$7.28$12.4B
2024$64.2Bn/a$17.1B$6.74$18.1B
2023$60.1Bn/a$365M$0.14$9.1B
2022$59.3Bn/a$14.5B$5.71$14.7B
2021$48.7Bn/a$13B$5.14$8.7B
2020$41.5Bn/a$7.1B$2.78$5.8B

Latest SEC filings

What Merck & Co., Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 7, 2026
    Quarterly report 10-Q · period to June 30, 2026
  2. August 7, 2026
  3. August 4, 2026
  4. June 24, 2026
  5. June 24, 2026
  6. June 24, 2026
  7. May 29, 2026
  8. May 28, 2026
  9. May 22, 2026
  10. May 20, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 1, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about MRK

What does Merck & Co., Inc. do?

Merck & Co. develops and manufactures prescription medicines, vaccines, and animal health products. The company sells its drugs to hospitals, pharmacies, and healthcare providers worldwide. It is known for producing cancer therapies, diabetes treatments, and vaccines for human and animal use. Its shares trade on NYSE under the ticker MRK.

Is Merck & Co., Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $3.2B on revenue of $66.6B, a net margin of 4.8%.

How much revenue does Merck & Co., Inc. make?

Over the twelve months to June 30, 2026 Merck & Co., Inc. reported revenue of $66.6B. That is 4.6% more than a year earlier.

When did Merck & Co., Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 1, 2026.

Similar companies

Follow MRK

Get an email when Merck & Co., Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow MRK: get an email when it files

Where the numbers come from

Financial figures are the values Merck & Co., Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.